Biocon Readies for U.S., Europe Off-Patent Mart

India’s largest biotechnology company Biocon is planning to tap the potential of biosimilars (generics or copycat versions of biotech drugs going off patent) in the regulated markets of the U.S. and Europe, besides taking Insugen, its own version of insulin, to the global markets in a big way.
The Business Standard